GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » Price-to-Owner-Earnings

CTI BioPharma (FRA:CEPS) Price-to-Owner-Earnings : (As of Jun. 20, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma Price-to-Owner-Earnings?

As of today (2024-06-20), CTI BioPharma's share price is €8.106. CTI BioPharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for CTI BioPharma's Price-to-Owner-Earnings or its related term are showing as below:


FRA:CEPS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.555
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-20), CTI BioPharma's share price is €8.106. CTI BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was €-0.56. Therefore, CTI BioPharma's PE Ratio (TTM) for today is At Loss.

As of today (2024-06-20), CTI BioPharma's share price is €8.106. CTI BioPharma's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.56. Therefore, CTI BioPharma's PE Ratio without NRI for today is At Loss.


CTI BioPharma Price-to-Owner-Earnings Historical Data

The historical data trend for CTI BioPharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Price-to-Owner-Earnings Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CTI BioPharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, CTI BioPharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTI BioPharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's Price-to-Owner-Earnings falls into.



CTI BioPharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CTI BioPharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=8.106/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CTI BioPharma  (FRA:CEPS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CTI BioPharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CTI BioPharma (FRA:CEPS) Business Description

Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines